DFTX ▲ +4.2% - Definium Therapeutics, Inc.
$DFTX JPMorgan initiated coverage of Definium Therapeutics with an Overweight rating and $84 price target. The company's lead asset DT120 ODT is being developed as a treatment for various neuropsychiatric disorders, the analyst tells investors in a research note. As a psychedelic drug, JPMorgan sees DT120 ODT as potentially shifting the treatment paradigm in neuropsychiatry. It believes the asset has "intriguing pipeline-in-a-product potential."
09-OCT-2026 08:30 AM ET
Share this post
More filings for $DFTX
DFTX - Definium Therapeutics, Inc. - SEC Filing Update (16-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 16, 2026DFTX ▲ +8.1% - Definium Therapeutics, Inc.Nov 9, 2026DFTX - Definium Therapeutics, Inc. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026DFTX ▼ -0.4% - Definium Therapeutics, Inc.Oct 29, 2026DFTX ▲ +6.6% - Definium Therapeutics, Inc.Sep 14, 2026DFTX ▲ +1.2% - Definium Therapeutics, Inc.Sep 8, 2026
View full $DFTX filing history →💬 Comments
Loading comments…
Leave a comment
